Funding
- Public FundsRetos-Colaboración - 2017 (RTC-2017-5867-1)- 2019 (RTC-2019-6825-1)CDTI 2017 (IDI-20180106)
CPP2021-008554
financiado por MICIU/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTRCPP2023-010519
financiado por MCIU/ AEI / 10.13039/501100011033 / FEDER, UE
- Retos-Desarrollo - 2014 (RTC-2014-2412)- 2016 (RTC-2016-5686)Innpacto 2012 (PT-2012-0561-010000)Torres Quevedo - 2012, 2013, 2014, 2015, 2017, 2018, 2023
- AMMIC Project / RIS3CAT 2016-2020Proyecto cofinanciado de la Unión Europea a través del Programa FEDER 2014-2020
- RD14-1-0114 Desenvolupament MIN-102
- Innovative SME
- ENISA Jóvenes Emprendedores 2012
- TECNIOspring PLUS
Aquest projecte ha rebut finançament del programa de recerca i innovació Horitzó 2020 de la Unió Europea sota l'acord de subvenció Marie Skłodowska-Curie No 712949 (TECNIOspring PLUS), així com de l'Agència per a la Competitivitat de l'Empresa de la Generalitat de Catalunya
- The NEXUS trial received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No No. 822968
- NewsSee allMinoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett syndrome (TREE study)Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral AdrenoleukodystrophyLeriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in BrainUpdate on Regulatory Review of NEZGLYAL® (leriglitazone) in the EURare Disease Day 2024 - Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy – special film launchedUpdate on Regulatory Review of leriglitazone in the EUMinoryx announces enrollment of first patients with cerebral Adrenoleukodystrophy (cALD) in US Phase 3 clinical trial, CALYXMinoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral AdrenoleukodystrophyMinoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy
Privacy Settings